Von Willebrand Disease (vWD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Von Willebrand Disease (vWD) – Drugs In Development, 2024 report and make more profitable business decisions.
Von Willebrand Disease (vWD) is a very common bleeding disorder that can be either inherited or acquired. It is caused by a deficiency of pro-von Willebrand factor which is a glycoprotein that plays a major role in hemostasis. This condition is classified as type-1, type-2, and acquired. People with this disease experience excess bleeding or a long duration for the bleeding to stop. It is usually diagnosed when a person experiences prolonged bleeding, recurrent bruising, and in females heavy or prolonged menstrual bleeding while undergoing dental extractions. Diagnosis is carried out by laboratory examinations like CBP, bleeding and clotting time, von Willebrand factor levels, and factor VIII activity. There is no specific treatment for von Willebrand’s condition, either symptomatic or measures to stop excess bleeding are considered. The most used medications are tranexamic acid for excess bleeding, desmopressin and von Willebrand factor concentrate.
The Von Willebrand Disease (vWD) drugs in development market research report provide comprehensive information on the therapeutics under development for Von Willebrand Disease (vWD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Von Willebrand Disease (vWD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Von Willebrand Disease (vWD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Von Willebrand Disease (vWD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Von Willebrand Disease (vWD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Von Willebrand Disease (vWD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Band Therapeutics LLCBeijing Neoletix Biological Technology Co Ltd
Bioviz Technologies Pvt Ltd
China Resources Boya Bio-pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
GC Biopharma Corp
Hemab ApS
Pfizer Inc
Sanofi
Takeda Pharmaceutical Co Ltd
Vega Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Von Willebrand Disease (vWD) reports